SOURCE: Algeta ASA

February 10, 2006 04:23 ET

Algeta ASA - Interim data from Phase II clinical study of Alpharadin as a treatment for bone metastases in prostate cancer patients to be presented at 2006 Prostate Cancer Symposium

OSLO, NORWAY -- (MARKET WIRE) -- February 10, 2006 --

Oslo, Norway, February 10, 2006 - Algeta ASA is pleased to announce that an abstract relating to interim clinical data from a Phase II trial of its lead product Alpharadin (Radium-223) has been accepted for presentation at the 2006 Prostate Cancer Symposium in San Francisco, CA, February 24-26, 2006. A poster discussing the interim results will be presented in General Poster Session E between 11.30 and 13.00 on February 26, 2006.

Alpharadin is a novel bone-seeking radiopharmaceutical currently in Phase II trials as a potential new treatment for bone metastases in prostate cancer patients.

The present trial (BC1-02) was initiated to study the therapeutic efficacy of Alpharadin in hormone-refractory prostate cancer patients with painful skeletal metastases using biomarkers and clinical endpoints as outcome measures.


For further information, please contact:

Dr Thomas Ramdahl                                +47 23 00 79 90
CEO, Algeta ASA

Mark Swallow PhD / Helena Podd                   +44 (0)207 638
9571
Citigate Dewe Rogerson

Notes to Editors

About Algeta ASA

Algeta ASA, headquartered in Oslo, Norway, is a private therapeutics company dedicated to the development of novel anticancer therapeutics based on alpha particle emitting radionuclides. The Company was founded in 1997 as Anticancer Therapeutic Inventions.

Algeta's lead product candidate, Alpharadin, is a novel bone- seeking experimental radiopharmaceutical based on the alpha particle emitter radium-223. Alpharadin is currently in Phase II clinical trials as a potential new treatment for bone metastases from prostate cancer.

An estimated 1.5 million patients worldwide suffer from bone metastases and there are approximately 300,000 new cases per year. Prostate and breast cancers account for more than 80% of all cases. Median survival for patients is three years and there are no effective therapies.

Alpha emitters have not until recently been a significant therapeutic modality. However, discoveries in radiochemistry and recent advances in the understanding of tumor and radiation biology led Algeta's scientific founders - Roy Larsen and Oyvind Bruland - to conceive how the unique features of alpha emitters, such as high potency and short range, could be exploited to create new therapeutic candidates promising unrivalled potency without unacceptable toxicities.

For more information, visit us at www.algeta.com.


Copyright © Hugin ASA 2006. All rights reserved.

Contact Information